Whole Genome Sequencing vs Whole Exome Sequencing: A Practical Comparison

Table of Contents

Whole genome sequencing (WGS) and whole exome sequencing (WES) answer different questions at very different price points. Understanding the trade-offs helps you spend your sequencing budget where it matters most.

What each approach actually sequences

WGS sequences the entire genome — all 3 billion base pairs in humans, including coding regions, introns, regulatory elements, intergenic DNA, and mitochondrial DNA. No targeted enrichment needed.

WES sequences only the protein-coding exons (~1–2% of the human genome) using hybrid capture probes that pull down exonic fragments before sequencing. Most disease-causing variants known to date are in coding regions, which is why WES is so popular in clinical genetics.

Comparison summary

PropertyWGSWES
Genome coverage~100%~1–2% (exons)
Typical depth30–60×100–200×
Detects coding variantsYesYes
Detects non-coding variantsYesNo
Detects structural variantsYes (best)Limited
Detects copy number variantsYes (well)Possible but harder
CostHigherLower
Storage and computeHigherLower

When WGS makes sense

  • Suspected non-coding contributors to disease (regulatory variants, splicing, deep intronic mutations)
  • Structural variant detection — translocations, large deletions, inversions
  • Population genomics and association studies
  • Cancer genomics where structural variants matter
  • Research applications where cost is less constrained than completeness

When WES makes sense

  • Diagnostic odyssey for suspected Mendelian disorders
  • Clinical genetics where reimbursement is geared toward coding variants
  • Tumor profiling for actionable mutations — most therapeutic targets are coding
  • Large-cohort studies where budget per sample matters more than completeness

Hidden differences

  • WES has uneven coverage. Capture efficiency varies across exons; some regions are underrepresented or missed entirely.
  • WGS has more uniform coverage and better captures GC-rich regions like first exons of many genes.
  • WES requires deeper sequencing (100–200×) to call low-frequency variants reliably; WGS at 30× often performs as well or better.
  • Mitochondrial DNA is automatically captured at high depth in WGS; WES coverage of mtDNA depends on the kit.

Targeted alternatives

  • Targeted gene panels sequence 50–500 genes at very high depth — ideal for clinical oncology
  • RNA-seq identifies expressed variants and is increasingly used as a complementary diagnostic
  • Long-read WGS (PacBio, ONT) is the emerging gold standard for structural variants and complex regions

WGS prices have collapsed faster than WES — the gap that made WES economically obvious has narrowed considerably. If your question is purely about coding variants in a budget-constrained study, WES still makes sense. If non-coding variation, structural variants, or future-proofing matters, WGS is the better long-term choice.

Featured Articles

The Iran War Is Now Hitting Pharma Supply Chains Directly
Daily Updates

The Iran War Is Now Hitting Pharma Supply Chains Directly

The Iran war’s impact on pharmaceutical supply chains is no longer theoretical. Evonik, a major supplier of pharma-grade amino and keto acids, announced a 15% price increase effective immediately, citing rising energy, raw material, and shipping costs caused by the conflict. This is the first

Read More »
Makary Is Out. The FDA Has No Permanent Commissioner.
Daily Updates

Makary Is Out. The FDA Has No Permanent Commissioner.

It’s over. FDA Commissioner Marty Makary resigned on Tuesday after 13 months in the role. The resignation followed days of reporting that the White House had signed off on a plan to replace him. The final trigger was a disagreement over flavored e-cigarette authorization, which

Read More »

Join 85,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters